These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 30005773)

  • 41. Oncologic safety of breast-conserving surgery compared to mastectomy in patients receiving neoadjuvant chemotherapy for locally advanced breast cancer.
    Cho JH; Park JM; Park HS; Park S; Kim SI; Park BW
    J Surg Oncol; 2013 Dec; 108(8):531-6. PubMed ID: 24115142
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predictors of Response and Survival Outcomes of Triple Negative Breast Cancer Receiving Neoadjuvant Chemotherapy.
    Zhu M; Yu Y; Shao X; Zhu L; Wang L
    Chemotherapy; 2020; 65(3-4):101-109. PubMed ID: 32894832
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Potential role of targeted therapies in the treatment of triple-negative breast cancer.
    Jia LY; Shanmugam MK; Sethi G; Bishayee A
    Anticancer Drugs; 2016 Mar; 27(3):147-55. PubMed ID: 26682525
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment patterns, healthcare resource utilization and outcomes for early stage triple-negative breast cancer in Japan.
    Sanno H; Taniguchi K; Yoshimoto Y; Saji S
    Future Oncol; 2024 Apr; 20(13):833-849. PubMed ID: 38305038
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Advances in small-molecule drug discovery for triple-negative breast cancer.
    Fosu-Mensah N; Peris MS; Weeks HP; Cai J; Westwell AD
    Future Med Chem; 2015; 7(15):2019-39. PubMed ID: 26495746
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
    Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
    BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting.
    Gamucci T; Pizzuti L; Sperduti I; Mentuccia L; Vaccaro A; Moscetti L; Marchetti P; Carbognin L; Michelotti A; Iezzi L; Cassano A; Grassadonia A; Astone A; Botticelli A; Magnolfi E; Di Lauro L; Sergi D; Fuso P; Tinari N; Barba M; Maugeri-Saccà M; Landucci E; Conti F; Sanguineti G; De Tursi M; Iafrate G; Giordano A; Ciliberto G; Natoli C; Vici P
    J Cell Physiol; 2018 Mar; 233(3):2313-2323. PubMed ID: 28710865
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Updates in Neoadjuvant Therapy for Triple Negative Breast Cancer.
    Tufano AM; Teplinsky E; Landry CA
    Clin Breast Cancer; 2021 Feb; 21(1):1-9. PubMed ID: 32800492
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial.
    Zhang P; Yin Y; Mo H; Zhang B; Wang X; Li Q; Yuan P; Wang J; Zheng S; Cai R; Ma F; Fan Y; Xu B
    Oncotarget; 2016 Sep; 7(37):60647-60656. PubMed ID: 27447966
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inflammatory TNBC Breast Cancer: Demography and Clinical Outcome in a Large Cohort of Patients With TNBC.
    Biswas T; Efird JT; Prasad S; James SE; Walker PR; Zagar TM
    Clin Breast Cancer; 2016 Jun; 16(3):212-6. PubMed ID: 26988771
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of Local and Distant Recurrence Patterns in Patients with Triple-Negative Breast Cancer According to Age.
    Radosa JC; Eaton A; Stempel M; Khander A; Liedtke C; Solomayer EF; Karsten M; Pilewskie M; Morrow M; King TA
    Ann Surg Oncol; 2017 Mar; 24(3):698-704. PubMed ID: 27783163
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer.
    Nabholtz JM; Chalabi N; Radosevic-Robin N; Dauplat MM; Mouret-Reynier MA; Van Praagh I; Servent V; Jacquin JP; Benmammar KE; Kullab S; Bahadoor MR; Kwiatkowski F; Cayre A; Abrial C; Durando X; Bignon YJ; Chollet P; Penault-Llorca F
    Int J Cancer; 2016 May; 138(9):2274-80. PubMed ID: 26649807
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predictive factors and patterns of recurrence in patients with triple negative breast cancer.
    Steward L; Conant L; Gao F; Margenthaler JA
    Ann Surg Oncol; 2014 Jul; 21(7):2165-71. PubMed ID: 24558065
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New treatment strategies for patients with triple-negative breast cancer.
    Liedtke C; Rody A
    Curr Opin Obstet Gynecol; 2015 Feb; 27(1):77-84. PubMed ID: 25502428
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeting autophagic cancer stem-cells to reverse chemoresistance in human triple negative breast cancer.
    Bousquet G; El Bouchtaoui M; Sophie T; Leboeuf C; de Bazelaire C; Ratajczak P; Giacchetti S; de Roquancourt A; Bertheau P; Verneuil L; Feugeas JP; Espié M; Janin A
    Oncotarget; 2017 May; 8(21):35205-35221. PubMed ID: 28445132
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients.
    Ring BZ; Hout DR; Morris SW; Lawrence K; Schweitzer BL; Bailey DB; Lehmann BD; Pietenpol JA; Seitz RS
    BMC Cancer; 2016 Feb; 16():143. PubMed ID: 26908167
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
    Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
    Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Brain Metastasis of Triple Negative Breast Cancer after Pathological Complete Response to Neoadjuvant Chemotherapy - A Case Report].
    Sakata E; Endo Y; Miyahira A; Mio K; Yoshida K; Hashidate H; Shibuya H; Sato C; Higuchi T; Makino H
    Gan To Kagaku Ryoho; 2018 Jan; 45(1):184-186. PubMed ID: 29362349
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic role of adjuvant radiotherapy in triple-negative breast cancer: A historical cohort study.
    Bhoo-Pathy N; Verkooijen HM; Wong FY; Pignol JP; Kwong A; Tan EY; Aishah Taib N; Nei WL; Ho GF; Tan B; Chan P; Lee SC; Hartman M; Yip CH; Dent R
    Int J Cancer; 2015 Nov; 137(10):2504-12. PubMed ID: 26018878
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Magnetic Resonance Imaging after Completion of Neoadjuvant Chemotherapy Can Accurately Discriminate between No Residual Carcinoma and Residual Ductal Carcinoma In Situ in Patients with Triple-Negative Breast Cancer.
    Park S; Yoon JH; Sohn J; Park HS; Moon HJ; Kim MJ; Kim EK; Kim SI; Park BW
    PLoS One; 2016; 11(2):e0149347. PubMed ID: 26866475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.